Trevi Therapeutics announced that data from its Phase 2a RIVER trial of nalbuphine ER for refractory chronic cough (RCC) will be highlighted in two poster presentations at the European Respiratory Society (ERS) Congress 2025. The congress is scheduled from September 27 to October 1 in Amsterdam, Netherlands.
Two late-breaking abstracts will be presented, focusing on the efficacy and safety of nalbuphine extended-release in RCC, and a responder analysis from the RIVER trial. This provides further scientific validation and dissemination of the positive clinical results.
The Phase 2a RIVER trial previously demonstrated a statistically significant reduction in 24-hour cough frequency in RCC patients. Featuring these results at a major international conference broadens awareness among the medical community regarding Haduvio's potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.